Source: International Congress 2019 – Pleural disease: applying the evidence
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
U. Bodtger (Næstved, Denmark), K. Armbruster (Copenhagen, Denmark), S. Skaarup (Aarhus, Denmark), H. Kirstein (Aalborg, Denmark), C. Laursen (Odense , Denmark). Heterogeneous delivery of definitive interventions in malignant pleural effusions – results from a Danish survey.. 3088

Member's Comments

No comment yet.

Related content which might interest you: A Dutch web-survey on management of malignant pleural effusions Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions Year: 2011 ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma Source: Guideline 2020 Year: 2020 ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma Source: Eur Respir J, 55 (6) 1900953; 10.1183/13993003.00953-2019 Year: 2020 Optimal management of symptomatic malignant pleural effusions: individualised care Source: Virtual Congress 2021 – Hot news from the pleura Year: 2021 The necessity of examination of patients with pleural effusions by oncological programme Source: Eur Respir J 2006; 28: Suppl. 50, 75s Year: 2006 Are patients with malignant pleural effusions being referred appropriately for surgical intervention? Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008 ERS/EACTS statement on the management of malignant pleural effusions Source: Guideline 2018 Year: 2018 ERS/EACTS statement on the management of malignant pleural effusions Source: Eur Respir J, 52 (1) 1800349; 10.1183/13993003.00349-2018 Year: 2018 Ambulatory management of malignant pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 629s Year: 2004 The impact of multimodal treatment approaches in patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology Year: 2010 Early pleural fluid control is warranted to prevent reaccumulation of malignant pleural effusion in oncogene-driven lung cancer Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding Year: 2019 Ideal volume sampling in the diagnosis of malignant pleural effusions Source: Annual Congress 2012 - Clinical issues in malignant pleural effusions Year: 2012 A comparative study of conventional cytology and cell block method in the diagnosis of malignant pleural effusion. Source: International Congress 2018 – Lung cancer: new tools for diagnosis and patient assessment Year: 2018 Blind pleural biopsy in the study of undiagnosed pleural effusion: results and complications Source: Virtual Congress 2020 – Interventional pulmonology: the pleura and bronchoscopic treatment of emphysema Year: 2020 Malignant pleural effusions: diagnosis and management Source: International Congress 2017 – PG5 Pleural disease management Year: 2017 Malignant pleural effusions: from the diagnosis to the management Source: International Congress 2015 – ME2 Malignant pleural effusions: from diagnosis to management Year: 2015 Thoracoscopic evaluation of the effect of tumour burden on the outcome of pleurodesis in malignant pleural effusion Source: Virtual Congress 2021 – Pleural disease and bronchoscopic lung volume reduction Year: 2021 Malignant pleural effusion survival prognostication in an Asian population Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding Year: 2019 Outcomes of cytology positive malignant pleural effusions; do certain malignancies predispose patients to trapped lung? Source: International Congress 2019 – Novel approaches to pleural effusion: should I change my practice? Year: 2019 Predictors of successful pleurodesis for patients with malignant pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 493s Year: 2004